These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C; Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832 [TBL] [Abstract][Full Text] [Related]
5. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Ostadal P; Steg PG; Poulouin Y; Bhatt DL; Bittner VA; Chua T; Diaz R; Goodman SG; Huo Y; Jukema JW; Karpov Y; Pordy R; Scemama M; Szarek M; White HD; Schwartz GG; Lancet Diabetes Endocrinol; 2022 May; 10(5):330-340. PubMed ID: 35378068 [TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M; Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437 [TBL] [Abstract][Full Text] [Related]